Human gene variants linked to enhanced NLRP3 activity limit intramacrophage growth of Mycobacterium tuberculosis

Daniel Eklund1, Amanda Welin, Henrik Andersson

  • 1Division of Microbiology and Molecular Medicine.

Insights

Gain-of-function variants in NLRP3 and CARD8 inflammasome genes offer protection against tuberculosis. These genetic variations in macrophages enhance control of Mycobacterium tuberculosis bacterial growth, suggesting a host-protective role.

Area of Science:

  • Immunology
  • Infectious Diseases
  • Genetics

Background:

  • The NLRP3 inflammasome and interleukin 1β generation are crucial in macrophage immune responses to various stimuli.
  • Inflammasome components, including NLRP3 and CARD8, are implicated in inflammatory disorders through genetic variations.
  • Mycobacterium tuberculosis infection poses a significant global health challenge, necessitating a deeper understanding of host-pathogen interactions.

Purpose of the Study:

  • To investigate the role of gain-of-function gene variants in inflammasome components (NLRP3 and CARD8) during Mycobacterium tuberculosis infection.
  • To determine if specific genetic variants associated with inflammatory disorders confer a protective effect against tuberculosis in human macrophages.

Main Methods:

  • Isolation of primary human macrophages from individuals with known genetic variants in NLRP3 and CARD8.
  • Infection of these isolated macrophages with virulent strains of Mycobacterium tuberculosis.
  • Assessment of bacterial growth control within macrophages harboring specific inflammasome gene variants.

Main Results:

  • Gain-of-function variants in NLRP3 and CARD8, typically linked to inflammatory conditions, were found to have a host-protective role during M. tuberculosis infection.
  • Macrophages from patients and healthy donors carrying combined NLRP3 and CARD8 genetic variants demonstrated significantly increased control of bacterial growth.
  • These findings highlight a novel protective mechanism against mycobacterial infection mediated by specific inflammasome gene variants.

Conclusions:

  • Genetic variants in NLRP3 and CARD8, previously associated with inflammatory disorders, confer a protective advantage against Mycobacterium tuberculosis infection.
  • Targeting or understanding the function of these inflammasome variants could offer new therapeutic strategies for tuberculosis.
  • The study underscores the complex, context-dependent role of inflammasomes in host defense against bacterial pathogens.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.7K
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
3.1K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160